Literature DB >> 21821309

Calciphylaxis: a systematic review of existing and emerging therapies.

Chetan Vedvyas1, Laura S Winterfield, Ruth Ann Vleugels.   

Abstract

Calciphylaxis, also known as calcific uremic arteriolopathy, is a cutaneous ischemic small vessel vasculopathy seen in 1 to 4% of patients with chronic kidney disease on hemodialysis. It is associated with extreme pain and a 60 to 80% mortality rate in the setting of few and frequently ineffective therapeutic options, although this may be changing based on reports of success with newer therapies.
Copyright © 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21821309     DOI: 10.1016/j.jaad.2011.06.009

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  29 in total

Review 1.  Calciphylaxis: from the disease to the diseased.

Authors:  Tiago M Oliveira; João M Frazão
Journal:  J Nephrol       Date:  2015-04-03       Impact factor: 3.902

Review 2.  Calciphylaxis: diagnosis and clinical features.

Authors:  Matsuhiko Hayashi
Journal:  Clin Exp Nephrol       Date:  2013-02-21       Impact factor: 2.801

Review 3.  Warfarin-Associated Nonuremic Calciphylaxis.

Authors:  Wesley Yung-Hsu Yu; Tina Bhutani; Rachel Kornik; Laura B Pincus; Theodora Mauro; Michael D Rosenblum; Lindy P Fox
Journal:  JAMA Dermatol       Date:  2017-03-01       Impact factor: 10.282

4.  Multidisciplinary management of calciphylaxis: a series of 5 patients at a single facility.

Authors:  Tomohiro Saito; Yuuki Mima; Motonori Sugiyama; Nozomi Miyazawa; Ayana Iida; Nobuhiro Kanazawa; Taihei Suzuki; Yasuto Shikida; Toma Hamada; Yukihiro Wada; Masahide Mizobuchi; Hirokazu Honda
Journal:  CEN Case Rep       Date:  2019-12-17

Review 5.  Calciphylaxis: risk factors, diagnosis, and treatment.

Authors:  Sagar U Nigwekar; Daniela Kroshinsky; Rosalynn M Nazarian; Jeremy Goverman; Rajeev Malhotra; Vicki Ann Jackson; Mihir M Kamdar; David J R Steele; Ravi I Thadhani
Journal:  Am J Kidney Dis       Date:  2015-05-07       Impact factor: 8.860

6.  Benefits of intralesional injections of sodium thiosulfate in the treatment of calciphylaxis.

Authors:  Kirsi Isoherranen; Laura Bouchard; Nicolas Kluger
Journal:  Int Wound J       Date:  2017-03-21       Impact factor: 3.315

7.  Nonuremic calciphylaxis precipitated by teriparatide [rhPTH(1-34)] therapy in the setting of chronic warfarin and glucocorticoid treatment.

Authors:  E K Spanakis; D E Sellmeyer
Journal:  Osteoporos Int       Date:  2013-11-29       Impact factor: 4.507

8.  A case of calciphylaxis in a patient with hypoparathyroidism and normal renal function.

Authors:  Blake L Erdel; Rattan Juneja; Carmella Evans-Molina
Journal:  Endocr Pract       Date:  2014-06       Impact factor: 3.443

Review 9.  Calcific uraemic arteriolopathy: a rare disease with a potentially high impact on chronic kidney disease-mineral and bone disorder.

Authors:  Vincent M Brandenburg; Smeeta Sinha; Paula Specht; Markus Ketteler
Journal:  Pediatr Nephrol       Date:  2014-01-29       Impact factor: 3.714

10.  Raman spectroscopy for label-free identification of calciphylaxis.

Authors:  William R Lloyd; Shailesh Agarwal; Sagar U Nigwekar; Karen Esmonde-White; Shawn Loder; Shawn Fagan; Jeremy Goverman; Bjorn R Olsen; Dolrudee Jumlongras; Michael D Morris; Benjamin Levi
Journal:  J Biomed Opt       Date:  2015-08       Impact factor: 3.170

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.